Profiles of pro‐inflammatory cytokines in allogenic stem cell transplantation with post‐transplant cyclophosphamide
Sign Up to like & getrecommendations! Published in 2017 at "Cytokine"
DOI: 10.1016/j.cyto.2017.08.016
Abstract: Abstract Large number of studies was published about predictive value of cytokines for graft‐versus‐host disease (GVHD) after allogeneic stem cell transplantation. Recently, there has been a growing interest in GVHD prophylaxis with post‐transplant cyclophosphamide (PTCy).… read more here.
Keywords: transplant cyclophosphamide; cell transplantation; post transplant; stem cell ... See more keywords
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
Sign Up to like & getrecommendations! Published in 2021 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-021-01528-y
Abstract: Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at… read more here.
Keywords: post transplant; gvhd prophylaxis; post; gvhd ... See more keywords
Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2017.1318054
Abstract: ABSTRACT Introduction: Post transplant cyclophosphamide (PT/Cy) in association to other immunosuppressive agents or alone has emerged as a promising pharmacological strategy in the setting of allogeneic hematopoietic cell transplant (allo-HCT). Its safety profile and effectiveness… read more here.
Keywords: transplant cyclophosphamide; graft; transplant; post transplant ... See more keywords
Haploidentical Stem Cell Transplant With Post-transplant Cyclophosphamide for Chediak-Higashi Syndrome: A Very Rare Case Report
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000001977
Abstract: Chediak-Higashi syndrome is a rare immunodeficiency disorder for which hematopoietic stem cell transplant (HSCT) is the only curative treatment option. HSCT only corrects the hematologic and immunologic manifestations of the disease but neurologic complications may… read more here.
Keywords: transplant; higashi syndrome; transplant cyclophosphamide; post transplant ... See more keywords
ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of haematology"
DOI: 10.1111/ejh.13714
Abstract: During 2020, the concurrent novel COVID-19 pandemic lead to widespread cryopreservation of allogeneic HCT grafts based on NMDP and EBMT recommendations, in order to secure grafts before the start of conditioning chemotherapy. We sought to… read more here.
Keywords: transplant cyclophosphamide; cell; atg post; stem cell ... See more keywords
Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.816231
Abstract: Even with high-dose post-transplant cyclophosphamide (PT-Cy) which was initially introduced for graft-versus-host disease (GvHD) prevention in the setting of HLA-haploidentical transplantation, both acute and chronic GvHDs remain a major clinical challenge. Despite improvements in the… read more here.
Keywords: extracellular vesicles; host disease; transplant cyclophosphamide; post transplant ... See more keywords
Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23158748
Abstract: Non-relapse mortality due to GVHD and infections represents a major source of morbidity and mortality in pediatric HSCT recipients. Post-transplant cyclophosphamide (PTCy) has emerged as an effective and safe GVHD prophylaxis strategy, with improved GVHD… read more here.
Keywords: patients acute; transplant cyclophosphamide; post transplant; acute myeloid ... See more keywords